JP2004502446A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004502446A5 JP2004502446A5 JP2002509358A JP2002509358A JP2004502446A5 JP 2004502446 A5 JP2004502446 A5 JP 2004502446A5 JP 2002509358 A JP2002509358 A JP 2002509358A JP 2002509358 A JP2002509358 A JP 2002509358A JP 2004502446 A5 JP2004502446 A5 JP 2004502446A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- polynucleotide
- seq
- amino acid
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 description 16
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 239000002157 polynucleotide Substances 0.000 description 12
- 102000040430 polynucleotide Human genes 0.000 description 11
- 108091033319 polynucleotide Proteins 0.000 description 11
- 229960005486 vaccine Drugs 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- -1 amino Chemical group 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000031729 Bacteremia Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21646500P | 2000-07-06 | 2000-07-06 | |
| US60/216,465 | 2000-07-06 | ||
| PCT/CA2001/001001 WO2002004495A2 (en) | 2000-07-06 | 2001-07-06 | Streptococcus pyogenes antigen |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004502446A JP2004502446A (ja) | 2004-01-29 |
| JP2004502446A5 true JP2004502446A5 (enExample) | 2008-09-04 |
| JP4718099B2 JP4718099B2 (ja) | 2011-07-06 |
Family
ID=22807177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002509358A Expired - Fee Related JP4718099B2 (ja) | 2000-07-06 | 2001-07-06 | ストレプトコッカス・パイオジェンス抗原 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7247308B2 (enExample) |
| EP (1) | EP1297145B1 (enExample) |
| JP (1) | JP4718099B2 (enExample) |
| AT (1) | ATE412750T1 (enExample) |
| AU (1) | AU7227001A (enExample) |
| BR (1) | BR0112497A (enExample) |
| CA (1) | CA2413576C (enExample) |
| DE (1) | DE60136360D1 (enExample) |
| ES (1) | ES2316458T3 (enExample) |
| WO (1) | WO2002004495A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002004495A2 (en) * | 2000-07-06 | 2002-01-17 | Shire Biochem Inc. | Streptococcus pyogenes antigen |
| ATE439372T1 (de) | 2000-10-27 | 2009-08-15 | Novartis Vaccines & Diagnostic | Nukleinsäuren und proteine von gruppen a und b- streptokokken |
| US7595057B2 (en) * | 2000-12-21 | 2009-09-29 | Id Biomedical Corporation | Streptococcus pyogenes antigens and corresponding DNA fragments |
| WO2004018646A2 (en) * | 2002-08-26 | 2004-03-04 | Chiron Corporation | Conserved and specific streptococcal genomes |
| JP4875490B2 (ja) * | 2003-07-31 | 2012-02-15 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｙｏｇｅｎｅｓについての免疫原組成物 |
| CA2535863A1 (en) * | 2003-08-15 | 2005-02-24 | Id Biomedical Corporation | Polypeptides of streptococcus pyogenes |
| US8945589B2 (en) * | 2003-09-15 | 2015-02-03 | Novartis Vaccines And Diagnostics, Srl | Immunogenic compositions for Streptococcus agalactiae |
| US20060165716A1 (en) * | 2004-07-29 | 2006-07-27 | Telford John L | Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae |
| WO2006042027A2 (en) * | 2004-10-08 | 2006-04-20 | Novartis Vaccines And Diagnostics Inc. | Immunogenic and therapeutic compositions for streptococcus pyogenes |
| GB2428006A (en) * | 2005-07-07 | 2007-01-17 | Jevgenis Morov | AMI-3 vaccine comprising group A Streptococcus pyogenes bacteria |
| ATE522541T1 (de) * | 2006-06-09 | 2011-09-15 | Novartis Ag | Bakterielle adhäsine konformere |
| AU2007348285A1 (en) * | 2006-10-30 | 2008-09-12 | Novartis Ag | Immunogenic and therapeutic compositions for streptococcus pyogenes |
| CA2699513C (en) | 2007-09-12 | 2018-03-13 | Novartis Ag | Gas57 mutant antigens and gas57 antibodies |
| BRPI0821240B8 (pt) | 2007-12-21 | 2022-10-04 | Novartis Ag | formas mutantes de estreptolisina o |
| CA2838981C (en) | 2011-06-17 | 2020-09-08 | University Of Tennessee Research Foundation | Group a streptococcus multivalent vaccine |
| WO2014124446A1 (en) | 2013-02-11 | 2014-08-14 | University Of Tennessee Research Foundation | Group a streptococcal m-related proteins and methods of use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0916726A1 (en) | 1997-11-13 | 1999-05-19 | Rijksuniversiteit te Groningen | Attaching substances to micro-organisms |
| WO2002004495A2 (en) | 2000-07-06 | 2002-01-17 | Shire Biochem Inc. | Streptococcus pyogenes antigen |
-
2001
- 2001-07-06 WO PCT/CA2001/001001 patent/WO2002004495A2/en not_active Ceased
- 2001-07-06 US US10/332,231 patent/US7247308B2/en not_active Expired - Lifetime
- 2001-07-06 JP JP2002509358A patent/JP4718099B2/ja not_active Expired - Fee Related
- 2001-07-06 EP EP01951286A patent/EP1297145B1/en not_active Expired - Lifetime
- 2001-07-06 AU AU7227001A patent/AU7227001A/xx active Pending
- 2001-07-06 DE DE60136360T patent/DE60136360D1/de not_active Expired - Lifetime
- 2001-07-06 AT AT01951286T patent/ATE412750T1/de not_active IP Right Cessation
- 2001-07-06 BR BR0112497-8A patent/BR0112497A/pt not_active IP Right Cessation
- 2001-07-06 CA CA2413576A patent/CA2413576C/en not_active Expired - Fee Related
- 2001-07-06 ES ES01951286T patent/ES2316458T3/es not_active Expired - Lifetime
-
2007
- 2007-07-09 US US11/775,131 patent/US7811585B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9346860B2 (en) | Expression system | |
| JP2002510494A5 (enExample) | ||
| JP2002537791A5 (enExample) | ||
| JP2007502101A5 (enExample) | ||
| JP2004501618A5 (enExample) | ||
| CA2385325A1 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
| CA2356836A1 (en) | Novel streptococcus antigens | |
| RU2677799C2 (ru) | Модифицированные суперспиральные белки с улучшенными свойствами | |
| JP2002542827A5 (enExample) | ||
| DK2295065T3 (da) | Modificeret varmechockprotein-antigenpeptidkompleks | |
| CA2413576A1 (en) | Streptococcus pyogenes antigens | |
| JP2002542169A5 (enExample) | ||
| CN107737334B (zh) | 一种预防a型链球菌感染的广谱多联亚单位疫苗 | |
| CN104415329B (zh) | 一种抑制链球菌和/或预防链球菌感染的疫苗 | |
| AU743165B2 (en) | Live attenuated bacteria of the species Actinobacillus pleuropneumoniae | |
| JP2005512518A5 (enExample) | ||
| CN108671227B (zh) | 一种预防猪链球菌感染的广谱多联亚单位疫苗 | |
| JP2002516662A5 (enExample) | ||
| JP2004531235A5 (enExample) | ||
| JP2004529601A5 (enExample) | ||
| CA2438921A1 (en) | Streptococcus pyogenes polypeptides and corresponding dna fragments | |
| CN104800843A (zh) | 一种用于弓形虫感染预防的药剂及应用 | |
| CN102772795B (zh) | 布鲁氏菌鞭毛蛋白bmeii1112在制备布鲁氏菌亚单位疫苗中的应用 | |
| CN117187222A (zh) | 一种低细胞毒性的幽门螺杆菌尿素酶b蛋白突变体的疫苗组合物 | |
| CA2432525A1 (en) | Streptococcus pyogenes antigens and corresponding dna fragments |